Document Detail


The prophylaxis of AV nodal re-entry tachycardia.
MedLine Citation:
PMID:  6956473     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. Electrophysiology study and clinical follow-up were used to evaluate verapamil in the prophylaxis of refractory paroxysmal supraventricular tachycardia (PSVT) due to atrioventricular (AV) nodal re-entry in twenty-one patients. 2. Electrophysiologic variables and initiation and maintenance of re-entry were studied by programmed electrical stimulation before and after intravenous verapamil of 0.15 mg/kg. 3. Verapamil significantly increased AV nodal conduction time (AH interval), decreased the atrial pacing rate at which AV Wenckebach occurred and prolonged both effective and functional refractory periods of the AV node. 4. AV nodal re-entry was initiated in twenty out of twenty-one patients before intravenous verapamil. Re-entry could not be initiated in nine of the twenty patients after verapamil and was non-sustained in a further four patients. 5. Over a mean follow-up period of 20 months, seventeen of the twenty-one patients were symptomatically improved while taking oral verapamil 80-160 mg t.d.s. Of two patients who had no improvement on oral verapamil, one proceeded to surgical His bundle section. The patient in whom arrhythmia induction during electrophysiology study was only possible after intravenous verapamil had increased frequency of PSVT on the oral preparation. Two further patients had unacceptable side effects which necessitated cessation of the drug. 6. It was concluded that verapamil is a useful agent in prophylaxis of AV nodal re-entry and that observations during electrophysiology study may guide long-term management.
Authors:
A M Tonkin; L Shorne
Related Documents :
902383 - Sudden death after repair of tetralogy of fallot. electrocardiographic and electrophysi...
830223 - Clinical significance of prolonged sinoatrial conduction time.
6870203 - Roles of echocardiography and arrhythmia monitoring in the evaluation of patients with ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental pharmacology & physiology. Supplement     Volume:  6     ISSN:  0143-9294     ISO Abbreviation:  Clin Exp Pharmacol Physiol Suppl     Publication Date:  1982  
Date Detail:
Created Date:  1982-12-02     Completed Date:  1982-12-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7611484     Medline TA:  Clin Exp Pharmacol Physiol Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  135-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Adult
Aged
Atrioventricular Node / drug effects,  physiopathology*
Calcium Channel Blockers / pharmacology,  therapeutic use
Electrophysiology
Heart Conduction System / physiopathology*
Humans
Middle Aged
Sick Sinus Syndrome / drug therapy
Tachycardia / drug therapy*,  physiopathology
Verapamil / adverse effects,  pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of a slow channel inhibitor, verapamil, in the management of hypertension.
Next Document:  Verapamil: a selective antagonist of constrictor substances in dog coronary artery: implications for...